KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

Amneal Pharmaceuticals (AMRX) Cost of Revenue (2017 - 2026)

Amneal Pharmaceuticals has reported Cost of Revenue over the past 9 years, most recently at $517.1 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 10.58% year-over-year to $517.1 million; the TTM value through Dec 2025 reached $1.9 billion, up 7.44%, while the annual FY2025 figure was $1.9 billion, 7.44% up from the prior year.
  • Cost of Revenue for Q4 2025 was $517.1 million at Amneal Pharmaceuticals, up from $510.5 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $517.1 million in Q4 2025 and troughed at -$945.8 million in Q4 2021.
  • A 5-year average of $264.9 million and a median of $386.7 million in 2022 define the central range for Cost of Revenue.
  • Biggest five-year swings in Cost of Revenue: tumbled 375.77% in 2021 and later skyrocketed 48761.17% in 2024.
  • Year by year, Cost of Revenue stood at -$945.8 million in 2021, then surged by 141.7% to $394.4 million in 2022, then grew by 8.31% to $427.2 million in 2023, then increased by 9.48% to $467.6 million in 2024, then increased by 10.58% to $517.1 million in 2025.
  • Business Quant data shows Cost of Revenue for AMRX at $517.1 million in Q4 2025, $510.5 million in Q3 2025, and $438.3 million in Q2 2025.